Skip to main content
AMGN
NASDAQ Life Sciences

Amgen Q2 Earnings Crush Estimates, Raises 2026 Outlook on Drug Demand

Tom Rudovsky · Reported by Reuters
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Positive
Importance info
9
Price
$392.455
Mkt Cap
$210.497B
52W Low
$269.77
52W High
$398
52W Position info
45% above low
Off High info
1.4% below high
Rel. Volume info
1.3× avg
Market data snapshot near publication time

AMGN sits 45% above its 52-week low of $269.77.

Summary

Amgen delivered a strong Q2 beat, with adjusted EPS of $6.29 versus the $5.62 consensus and revenue of $10.1B against a $9.42B estimate. The company raised its full-year 2026 guidance to $22.30-$23.50 EPS on $38.2B-$39.4B in revenue, up from prior ranges. Growth was driven by key products: Repatha sales surged 37% to $953M, Evenity rose 38% to $714M, and rare disease drugs Uplizna and Tavneos grew 90% and 36%, respectively. The company also discontinued early-stage obesity candidate AMG 513, narrowing focus to MariTide, with Phase 3 data expected next year. This follows a turbulent period including the FDA's proposed Tavneos withdrawal and a recent cybersecurity breach, making the operational beat and raised guidance a notable positive signal. The results overshadow Merck's competing Lipfendra pill, with management citing unrivaled Repatha efficacy data, and MariTide Phase 3 readouts in 2027 are the next major catalyst.

At the time of this announcement, AMGN was trading at $392.46 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $210.5B. The 52-week trading range was $269.77 to $398.00. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Reuters.


Price Chart

Share this article

Copied!

AMGN - Latest Insights

AMGN
Nov 05, 2026, 3:00 AM EST
Source: Wiseek News
Importance Score:
8
Price at Filing: $477.40
Real-time Price: $461.50 info
Change: -$15.90 (-3%) info
Market Cap: $248.918B info
AMGN
Nov 03, 2026, 6:37 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $464.92
Real-time Price: $461.50 info
Change: -$3.42 (-0.74%) info
Market Cap: $248.918B info
AMGN
Nov 03, 2026, 4:05 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $463.00
Real-time Price: $461.50 info
Change: -$1.50 (-0.32%) info
Market Cap: $248.918B info
AMGN
Nov 03, 2026, 4:01 PM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $460.57
Real-time Price: $461.50 info
Change: +$0.930 (+0.20%) info
Market Cap: $248.918B info
AMGN
Oct 26, 2026, 9:23 AM EDT
Source: Benzinga
Importance Score:
7
Price at Filing: $448.79
Real-time Price: $461.50 info
Change: +$12.71 (+3%) info
Market Cap: $248.918B info